Voest, E E <br/><br/>
Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  1993 
 - 357-62 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>0344-5704 
<br/><br/><label>Standard No.: </label>10.1007/BF00686148  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Citrates--administration & dosage<br/>Citric Acid<br/>Deferoxamine--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Doxorubicin--administration & dosage<br/>Drug Combinations<br/>Drug Synergism<br/>Eye--drug effects<br/>Female<br/>Ferric Compounds--administration & dosage<br/>Humans<br/>Iron--pharmacokinetics<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Sorbitol--administration & dosage<br/>Tumor Cells, Cultured--drug effects